Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

RARE

Ultragenyx Pharmaceutical Inc

Feb 12 • 04:00PM ET

23.50

-0.38 -1.59 %

Healthcare • Biotechnology • USA • NASD

Feb 12, 6:37 PMUltragenyx posts Q4 and full-year 2025 results with 20% revenue growth, tightens spend and launches a strategic restructuring with a 10% workforce reduction, issues 2026 revenue guidance of $730–$760 million, and continues to target 2027 profitability despite the UX111 CRL delay.

Peers: BIIB VRTX ALNY BMRN AMGN REGN IONS CRSP NBIX PBYI

| Held by: XBI VTI VB VBK VXF IBB IWP SCHA IWF IWR

Index	-	P/E	-	EPS (ttm)	-5.84	Insider Own	6.94%	Shs Outstand	96.48M	Perf Week	-1.22%
Market Cap	2.27B	Forward P/E	-	EPS next Y	-0.71	Insider Trans	-0.30%	Shs Float	89.78M	Perf Month	-2.53%
Enterprise Value	2.40B	PEG	-	EPS next Q	-1.37	Inst Own	98.33%	Short Float	10.13%	Perf Quarter	-29.32%
Income	-575.44M	P/S	3.37	EPS this Y	34.18%	Inst Trans	3.96%	Short Ratio	3.64	Perf Half Y	-18.88%
Sales	672.72M	P/B	247.00	EPS next Y	81.43%	ROA	-37.91%	Short Interest	9.10M	Perf YTD	2.17%
Book/sh	0.10	P/C	3.08	EPS next 5Y	-	ROE	-656.54%	52W High	46.27 -49.21%	Perf Year	-45.89%
Cash/sh	7.64	P/FCF	-	EPS past 3/5Y	16.78% -13.72%	ROIC	-72.42%	52W Low	18.41 27.65%	Perf 3Y	-46.59%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	22.81% 19.95%	Gross Margin	83.85%	Volatility	4.75% 4.42%	Perf 5Y	-84.36%
Dividend TTM	-	EV/Sales	3.57	EPS Y/Y TTM	8.09%	Oper. Margin	-79.63%	ATR (14)	1.28	Perf 10Y	-57.09%
Dividend Ex-Date	-	Quick Ratio	1.74	Sales Y/Y TTM	20.08%	Profit Margin	-85.54%	RSI (14)	41.30	Recom	1.19
Dividend Gr. 3/5Y	- -	Current Ratio	1.89	EPS Q/Q	7.37%	SMA20	-1.86%	Beta	0.16	Target Price	58.16
Payout	-	Debt/Eq	-	Sales Q/Q	25.55%	SMA50	-15.34%	Rel Volume	0.76	Prev Close	23.88
Employees	1294	LT Debt/Eq	-	Earnings	Feb 12 AMC	SMA200	-25.22%	Avg Volume	2.50M	Price	23.50
IPO	Jan 31, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-18.07% 4.23%	Trades		Volume	1,893,584	Change	-1.59%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$65
Jul-28-25	Resumed	H.C. Wainwright	Buy	$80
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy	$56 → $67
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy	$162

Show Previous Ratings

Today 12:02AM	Ultragenyx Pharmaceutical Inc (RARE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Feb-12-26 08:14PM	Ultragenyx Pharmaceutical Q4 Earnings Call Highlights (MarketBeat)
06:00PM	Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:18PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update (GlobeNewswire)
Feb-09-26 03:30AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Feb-07-26 03:33AM	Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment (Insider Monkey)
Feb-06-26 07:40AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights RARE (Business Wire)
Feb-05-26 04:05PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update (GlobeNewswire)
10:00AM	Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-03-26 12:58PM	Ultragenyx Says Gene Therapy Shows Lasting Benefits, Slows Brain Decline In Fatal Childhood Disorder (Benzinga)
08:00AM	Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA) (GlobeNewswire)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
Jan-30-26 08:30AM	Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA (GlobeNewswire)
04:30PM	Loading…
Jan-23-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:05PM	Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies (PR Newswire)
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
Jan-12-26 10:11AM	Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery (Insider Monkey) +8.26%
07:30AM	Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference (GlobeNewswire)
Jan-09-26 03:16AM	Analysts Lower Ultragenyx (RARE) Target but Stay Bullish (Insider Monkey)
Jan-07-26 04:05PM	Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.36%
Jan-05-26 03:56AM	Novo launches Wegovy pill; Argenx to swap CEOs (BioPharma Dive)
Dec-31-25 09:50AM	RARE Rises on Completion of Rolling Submission for AAV Gene Therapy (Zacks)
09:40AM	DigitalBridge downgraded, Commvault initiated: Wall Streets top analyst calls (TipRanks)
09:01AM	Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? (Zacks)
07:37AM	Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall (Insider Monkey)
Dec-30-25 04:31PM	Stocks Fall Slightly in Thin Holiday Trade (Barchart) +15.52%
04:05PM	Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
03:58PM	Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today (Motley Fool)
12:39PM	Loading…
12:39PM	Why Ultragenyx Stock Dropped 42% and What Comes Next (Barrons.com)
11:06AM	Stocks Slip as Bond Yields Rise (Barchart)
11:00AM	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
09:36AM	DigitalBridge downgraded, Commvault initiated: Wall Street's top analyst calls (The Fly)
08:11AM	Company News for Dec 30, 2025 (Zacks)
06:17AM	S&P Futures Tread Water Ahead of FOMC Meeting Minutes (Barchart)
Dec-29-25 04:21PM	These Stocks Moved the Most Today: Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More (Barrons.com) -42.32%
03:34PM	Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today (Motley Fool)
01:18PM	These Stocks Are Moving the Most Today: Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More (Barrons.com)
01:05PM	These biotech stocks are getting hammered by shocking brittle-bone treatment study results (MarketWatch)
08:30AM	Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta (GlobeNewswire)
Dec-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-11-25 07:44AM	Is Ultragenyx Pharmaceutical Inc. (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Dec-04-25 11:30AM	Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-28-25 11:57AM	Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook (Insider Monkey)
Nov-24-25 04:30PM	Ultragenyx to Participate in Investor Conferences in December (GlobeNewswire)
Nov-21-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.73%
Nov-10-25 08:19PM	Morgan Stanley Reaffirms "Buy" Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT (Insider Monkey)
Nov-05-25 10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
12:10AM	Ultragenyx Pharmaceutical Inc (RARE) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Nov-04-25 05:30PM	Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 Earnings (Zacks)
05:15PM	Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
04:01PM	Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita (burosumab) for $400 Million to OMERS Life Sciences (GlobeNewswire)
Oct-30-25 08:00AM	Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups (GlobeNewswire)
Oct-29-25 10:00AM	Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-28-25 04:30PM	Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
10:00AM	Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-24-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.31%
Oct-17-25 09:16AM	Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength? (Zacks)
Oct-08-25 12:57AM	Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Oct-03-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-25 09:45AM	Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline (Insider Monkey)
Sep-30-25 04:05PM	Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President (GlobeNewswire)
04:00AM	Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Sep-29-25 08:28AM	FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza (Zacks)
Sep-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-25 09:17AM	Is Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity? (Insider Monkey)
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
Sep-09-25 11:12AM	RARE Reports Positive Long-Term Data From Metabolic Disorder Study (Zacks)
Sep-08-25 04:05PM	Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Aug-29-25 04:30PM	Ultragenyx to Participate at Investor Conferences in September (GlobeNewswire) +6.91%
Aug-21-25 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-18-25 08:00AM	Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Aug-06-25 11:43AM	Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
03:29AM	Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Aug-05-25 05:30PM	Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:06PM	Ultragenyx: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Aug-04-25 03:32PM	Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory (Insider Monkey)
Jul-31-25 04:05PM	Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome (GlobeNewswire)
11:35AM	Ultragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick Resubmission (Insider Monkey)
10:00AM	Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline (Zacks)
Jul-30-25 08:30AM	Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Jul-24-25 11:09AM	BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains? (Zacks)
Jul-22-25 10:05AM	FDA Rejects Replimunes Skin Cancer Treatment, Shares Sink (Bloomberg)
Jul-18-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-17-25 10:38AM	Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Jul-16-25 09:38AM	William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
07:00AM	New Pedestrian Access from Inner Belt to East Somerville MBTA Station Now Open to the Public (PR Newswire)
Jul-15-25 08:28AM	Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA (Zacks) -6.94%
05:46AM	Health Canada extends Evkeeza approval for children with HoFH (Pharmaceutical Technology)
Jul-14-25 04:24PM	Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection (Investor's Business Daily)
08:00AM	Health Canada Extends the Approval of Evkeeza (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
07:53AM	FDA rejects Ultragenyx gene therapy over manufacturing concerns (BioPharma Dive)
07:34AM	Ultragenyx receives complete response letter for UX111 BLA (Pharmaceutical Technology)
Jul-13-25 03:12PM	Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light (Insider Monkey)
Jul-11-25 04:30PM	Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
07:51AM	Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update (BioPharma Dive)

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Horn Howard	Chief Financial Officer	Feb 02 '26	Sale	23.56	3,061	72,117	88,935	Feb 03 12:00 PM
HOWARD HORN	Officer	Feb 02 '26	Proposed Sale	23.56	3,061	72,117		Feb 02 04:09 PM
Horn Howard	Chief Financial Officer	Jan 02 '26	Sale	22.84	3,150	71,946	91,996	Jan 05 04:07 PM
HOWARD HORN	Officer	Jan 02 '26	Proposed Sale	22.84	3,150	71,946		Jan 02 04:10 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Dec 29 '25	Sale	34.38	85	2,922	50,450	Dec 30 01:49 PM
Horn Howard	Chief Financial Officer	Dec 10 '25	Sale	36.38	3,081	112,087	95,146	Dec 11 12:10 PM
HOWARD HORN	Officer	Dec 10 '25	Proposed Sale	36.38	3,081	112,087		Dec 10 04:05 PM
Horn Howard	Chief Financial Officer	Oct 13 '25	Sale	31.51	7,942	250,252	98,227	Oct 14 12:15 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 18 '25	Sale	29.17	64	1,867	50,242	Sep 19 06:23 PM
KARAH PARSCHAUER	Officer	Sep 12 '25	Proposed Sale	31.17	2,450	76,366		Sep 12 04:17 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Sep 12 '25	Sale	31.17	2,450	76,366	73,271	Sep 12 04:11 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 05 '25	Sale	31.39	84	2,637	50,306	Sep 08 02:01 PM
Sanders Corazon (Corsee) D.	Director	Jun 20 '25	Sale	37.39	2,405	89,923	15,344	Jun 23 01:50 PM
CORAZON D. SANDERS	Director	Jun 20 '25	Proposed Sale	37.39	2,405	89,923		Jun 20 04:02 PM
Crombez Eric	EVP and Chief Medical Officer	May 05 '25	Sale	39.24	520	20,405	71,530	May 05 07:18 PM
Crombez Eric	EVP and Chief Medical Officer	Apr 21 '25	Sale	35.11	242	8,497	71,680	May 05 07:18 PM
Horn Howard	Chief Financial Officer	Mar 06 '25	Sale	40.40	1,785	72,114	106,169	Mar 10 12:53 PM
Kassberg Thomas Richard	CBO & EVP	Mar 03 '25	Sale	42.10	6,028	253,779	265,238	Mar 04 08:19 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 03 '25	Sale	42.10	12,846	540,817	75,287	Mar 04 08:18 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 03 '25	Sale	42.10	8,945	376,584	71,922	Mar 04 08:16 PM
Pinion John Richard	See Remarks	Mar 03 '25	Sale	42.10	14,439	607,882	107,766	Mar 04 08:12 PM
KAKKIS EMIL D	President & CEO	Mar 03 '25	Sale	42.10	73,434	3,091,571	641,731	Mar 04 08:10 PM
KAKKIS EMIL D	President & CEO	Feb 28 '25	Sale	42.48	25,000	1,062,000	2,158,985	Mar 04 08:10 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 03 '25	Sale	42.10	15,103	635,836	87,855	Mar 04 08:06 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 03 '25	Sale	42.10	967	40,711	50,265	Mar 04 08:00 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Feb 27 '25	Sale	42.88	2,990	128,224	54,991	Mar 03 01:58 PM
KAKKIS EMIL D	Officer	Feb 28 '25	Proposed Sale	42.48	25,000	1,062,100		Feb 28 04:11 PM
Parschauer Karah Herdman	Officer	Feb 27 '25	Proposed Sale	42.88	2,990	128,215		Feb 27 05:08 PM

Open in Screener

VIR

Vir Biotechnology Inc

Feb 12 • 04:00PM ET

7.71

+0.29 3.91 %

Healthcare • Biotechnology • USA • NASD

VIR Vir Biotechnology Inc daily Stock Chart

Peers: REGN MRNA LLY PFE JNJ GILD BNTX AZN-D SNY NVAX

| Held by: IJR VTI XBI IWM VB VBK SPSM VXF IWN IBB

Index	RUT	P/E	-	EPS (ttm)	-3.62	Insider Own	32.38%	Shs Outstand	139.02M	Perf Week	11.42%
Market Cap	1.07B	Forward P/E	-	EPS next Y	-2.91	Insider Trans	-6.43%	Shs Float	94.07M	Perf Month	22.19%
Enterprise Value	664.09M	PEG	-	EPS next Q	-0.49	Inst Own	54.12%	Short Float	13.00%	Perf Quarter	35.03%
Income	-499.65M	P/S	63.62	EPS this Y	12.47%	Inst Trans	-3.23%	Short Ratio	6.72	Perf Half Y	68.71%
Sales	16.86M	P/B	1.35	EPS next Y	13.26%	ROA	-39.69%	Short Interest	12.23M	Perf YTD	27.86%
Book/sh	5.73	P/C	2.11	EPS next 5Y	14.29%	ROE	-49.06%	52W High	10.01 -22.98%	Perf Year	-15.37%
Cash/sh	3.66	P/FCF	-	EPS past 3/5Y	- -18.74%	ROIC	-56.31%	52W Low	4.16 85.56%	Perf 3Y	-70.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-59.24% 55.77%	Gross Margin	26.74%	Volatility	6.24% 7.36%	Perf 5Y	-88.94%
Dividend TTM	-	EV/Sales	39.39	EPS Y/Y TTM	7.74%	Oper. Margin	-3081.69%	ATR (14)	0.47	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.25	Sales Y/Y TTM	-78.55%	Profit Margin	-2963.54%	RSI (14)	60.33	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	7.25	EPS Q/Q	24.91%	SMA20	6.34%	Beta	1.67	Target Price	16.33
Payout	-	Debt/Eq	0.13	Sales Q/Q	-89.92%	SMA50	16.47%	Rel Volume	0.87	Prev Close	7.42
Employees	408	LT Debt/Eq	0.11	Earnings	Feb 23 AMC	SMA200	36.34%	Avg Volume	1.82M	Price	7.71
IPO	Oct 11, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-38.64% -87.90%	Trades		Volume	1,589,114	Change	3.91%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-25	Initiated	Evercore ISI	Outperform	$12
Aug-27-25	Upgrade	BofA Securities	Neutral → Buy	$14
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral	$23 → $9
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral	$23 → $14
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight	$35 → $34
Feb-21-23	Upgrade	Goldman	Neutral → Buy	$41 → $53
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$18 → $30
Sep-14-22	Initiated	SVB Leerink	Outperform	$40
Sep-09-22	Initiated	Morgan Stanley	Underweight	$15
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral	$36 → $28
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform	$36
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral	$29 → $37
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$64 → $62
Jun-04-21	Resumed	Robert W. Baird	Neutral	$45
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight	$30
Jan-20-21	Reiterated	H.C. Wainwright	Buy	$100 → $125
Oct-05-20	Initiated	BofA Securities	Buy	$55
Sep-14-20	Upgrade	Goldman	Neutral → Buy	$48 → $54
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral	$29
Aug-20-20	Initiated	Needham	Buy	$62

Show Previous Ratings

Feb-09-26 04:05PM	Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Jan-27-26 10:50AM	Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks (PR Newswire)
Jan-12-26 08:00AM	Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones (Business Wire)
Jan-05-26 04:05PM	Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-16-25 04:05PM	Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program (Business Wire) -5.25%
04:05PM	Loading…
Nov-19-25 04:05PM	Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference (Business Wire)
Nov-09-25 06:07PM	Vir Biotechnology Announces AASLD The Liver Meeting Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile (Business Wire)
Nov-07-25 09:00AM	Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference (Business Wire)
Nov-06-25 12:04AM	Vir Biotechnology Inc (VIR) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com) -5.19%
Nov-05-25 05:45PM	Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 08:00AM	Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta (Business Wire) -6.04%
Oct-29-25 11:48AM	GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View (Zacks) -8.09%
Oct-22-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire) -5.56%
Oct-09-25 04:05PM	Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer (Business Wire)
09:27AM	Loading…
09:27AM	Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains? (Zacks)
Oct-07-25 08:00AM	Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting 2025 (Business Wire)
Aug-27-25 04:21PM	Vir Stock Soars After BofA Boosts Rating on Liver Therapy (GuruFocus.com) +17.79%
09:34AM	Micron initiated, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly)
Aug-25-25 04:05PM	Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-06-25 06:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -14.37%
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results (Business Wire)
08:05AM	Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta (Business Wire)
Jul-31-25 08:05AM	Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta (Business Wire)
Jul-30-25 11:42AM	GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise (Zacks)
10:00AM	Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-25-25 05:50AM	First subject dosed in Phase I trial of Vir Biotechnologys VIR-5525 (Clinical Trials Arena)
Jul-24-25 08:05AM	Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors (Business Wire)
Jul-22-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025 (Business Wire)
Jul-14-25 09:52AM	Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board (Business Wire)
09:40AM	Loading…
Jul-12-25 09:40AM	CoreWeave initiated, Texas Instruments upgraded: Wall Streets top analyst calls (TipRanks)
Jul-11-25 09:38AM	CoreWeave initiated, Texas Instruments upgraded: Wall Street's top analyst calls (The Fly)
Jul-10-25 09:31AM	Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? (Zacks)
May-28-25 04:05PM	Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Business Wire) +9.03%
May-20-25 04:05PM	Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit (Business Wire)
May-12-25 04:05PM	Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference (Business Wire) -11.32%
May-09-25 06:00AM	Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study (Business Wire) -6.01%
May-08-25 09:35AM	Q1 2025 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
03:31AM	Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-07-25 11:21PM	Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus (Seeking Alpha)
11:21PM	Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:15PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results (Business Wire)
Apr-30-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 (Business Wire)
11:45AM	GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance (Zacks)
Apr-24-25 09:30AM	Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 (Business Wire) +5.36%
Apr-09-25 09:43AM	Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple (Insider Monkey) +10.21%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-21-25 07:10AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results (PR Newswire)
Mar-13-25 08:05AM	Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta (Business Wire)
Feb-27-25 01:30PM	Q4 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) -11.85%
02:24AM	Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
Feb-26-25 05:45PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-19-25 04:05PM	Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-12-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 (Business Wire) +5.16%
Jan-23-25 06:35PM	Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now (Insider Monkey) +6.36% -5.09%
Jan-10-25 02:32PM	Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why (Benzinga)
Jan-09-25 08:30AM	Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 (Investing.com)
08:18AM	Vir Biotechnology Reports Promising Trial Results for Cancer Therapies (TipRanks)
Jan-08-25 04:06PM	Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment (Investor's Business Daily) +58.17%
07:45AM	Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC (Business Wire)
07:25AM	Vir Biotechnology price target lowered to $14 from $15 at BofA (TipRanks)
Dec-18-24 09:30AM	Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-24 04:05PM	Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta (Business Wire)
Dec-03-24 04:07PM	Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride (Investor's Business Daily) +12.88% -8.97%
09:02AM	Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients (Investor's Business Daily)
Nov-26-24 09:30AM	Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN Masked T-Cell Engager Programs (Business Wire)
Nov-25-24 09:30AM	Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-18-24 09:15PM	Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program (Business Wire) -12.23%
04:05PM	Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency (Business Wire)
Nov-15-24 01:39PM	What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? (Benzinga) -7.29%
11:00AM	Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting (Business Wire)
Nov-01-24 05:01PM	Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com) +23.63%
12:04AM	U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners (The Wall Street Journal)
Oct-31-24 05:20PM	Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (Business Wire)
Oct-18-24 03:04PM	State Street Corp's Strategic Acquisition in Vir Biotechnology Inc (GuruFocus.com)
Oct-17-24 04:30PM	Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 (Business Wire)
Oct-15-24 08:16AM	Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLDs The Liver Meeting 2024 (Business Wire)
Oct-03-24 04:00PM	Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (Business Wire) +5.59%
Sep-10-24 08:05AM	Vir Biotechnology Appoints Jason OByrne as Chief Financial Officer (Business Wire)
Sep-09-24 04:05PM	Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers (Business Wire)
Sep-04-24 08:30AM	Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 (GlobeNewswire)
Aug-22-24 08:05AM	Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-06-24 09:55AM	Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High? (Zacks)
Aug-01-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.34%
04:02PM	Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities (Business Wire)
04:01PM	Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers (Business Wire)
Jul-18-24 04:05PM	Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 (Business Wire)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
Jun-26-24 08:05AM	Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection (Business Wire)
Jun-06-24 01:26PM	Vir Biotechnology (VIR) Up on Positive Data From HDV Study (Zacks) -5.37%
Jun-05-24 02:51PM	Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday? (Benzinga) +19.66%
05:30AM	Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment (Business Wire)
May-29-24 04:05PM	Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire) -5.87%
08:05AM	Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer (Business Wire)
May-23-24 04:05PM	Vir Biotechnology to Host 2024 Annual Meeting of Stockholders (Business Wire) -6.33%
May-22-24 08:05AM	Multiple Abstracts Highlighting Vir Biotechnologys Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 (Business Wire) +11.36%

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SATO VICKI L	Director	Feb 02 '26	Sale	7.71	22,000	169,671	1,144,391	Feb 03 12:28 PM
SVF Endurance (Cayman) Limited	Stockholder	Jan 14 '26	Proposed Sale	6.82	1,251,303	8,533,886		Jan 14 09:00 PM
SATO VICKI L	Director	Jan 02 '26	Sale	5.93	22,000	130,383	1,166,391	Jan 05 01:57 PM
VICKI LEE SATO	Director	Jan 02 '26	Proposed Sale	6.03	66,000	397,980		Jan 02 04:29 PM
SVF Endurance (Cayman) Ltd	10% Owner	Dec 01 '25	Sale	5.98	191,854	1,147,786	13,728,924	Dec 03 04:30 PM
SATO VICKI L	Director	Dec 01 '25	Sale	6.00	22,000	132,070	1,188,391	Dec 02 07:48 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 26 '25	Sale	6.39	127,938	817,652	13,982,271	Dec 01 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 28 '25	Sale	6.44	61,493	396,015	13,920,778	Dec 01 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 25 '25	Sale	6.38	235,971	1,505,495	14,110,209	Nov 26 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 24 '25	Sale	6.15	227,803	1,400,783	14,346,180	Nov 26 04:30 PM
SVF Endurance (Cayman) Limited	10% Owner	Nov 25 '25	Proposed Sale	6.44	1,251,303	8,058,391		Nov 25 09:00 PM
O'Byrne Jason	EVP & Chief Financial Officer	Nov 17 '25	Sale	5.56	6,799	37,782	110,701	Nov 18 02:47 PM
O'Byrne Jason	Officer	Nov 17 '25	Proposed Sale	5.56	6,799	37,781		Nov 17 03:20 PM
de Verneuil Vanina	EVP, General Counsel, Corp Sec	Nov 05 '25	Sale	5.16	2,385	12,307	78,210	Nov 07 03:27 PM
de Verneuil Vanina	Officer	Nov 05 '25	Proposed Sale	5.16	2,385	12,307		Nov 05 09:47 AM
de Verneuil Vanina	EVP and General Counsel	Nov 03 '25	Sale	5.86	1,365	8,003	80,595	Nov 04 07:40 PM
SATO VICKI L	Director	Nov 03 '25	Sale	5.64	22,000	124,047	1,210,391	Nov 04 11:58 AM
de Verneuil Vanina	Officer	Nov 03 '25	Proposed Sale	5.86	1,365	8,003		Nov 03 03:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 28 '25	Sale	6.50	24,453	159,006	14,574,083	Oct 30 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 29 '25	Sale	6.49	100	649	14,573,983	Oct 30 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 27 '25	Sale	6.05	66,403	401,585	14,598,536	Oct 28 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 24 '25	Sale	5.96	46,696	278,285	14,664,939	Oct 28 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 23 '25	Sale	5.99	154,383	924,723	14,711,635	Oct 24 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 22 '25	Sale	6.15	144,266	887,654	14,866,018	Oct 24 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 20 '25	Sale	6.20	220,535	1,367,273	15,119,959	Oct 22 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 21 '25	Sale	6.30	109,675	690,974	15,010,284	Oct 22 04:30 PM
SVF Endurance (Cayman) Limited	10% Owner	Oct 21 '25	Proposed Sale	6.27	834,202	5,230,447		Oct 21 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 15 '25	Sale	6.07	16,671	101,196	15,353,338	Oct 17 04:15 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 16 '25	Sale	6.10	12,844	78,366	15,340,494	Oct 17 04:15 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 09 '25	Sale	6.14	249,060	1,529,926	15,372,309	Oct 14 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 10 '25	Sale	6.08	2,300	13,973	15,370,009	Oct 14 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 08 '25	Sale	6.05	466,242	2,819,785	15,621,369	Oct 09 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 07 '25	Sale	5.60	72,133	404,154	16,087,611	Oct 09 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 03 '25	Sale	5.56	450,342	2,501,785	16,233,699	Oct 07 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 06 '25	Sale	5.69	73,955	420,641	16,159,744	Oct 07 04:30 PM
SVF Endurance (Cayman) Limited	10% Owner	Oct 03 '25	Proposed Sale	5.71	1,668,404	9,526,587		Oct 03 05:00 PM
SATO VICKI L	Director	Oct 01 '25	Sale	5.84	22,000	128,396	1,232,391	Oct 02 11:53 AM
VICKI LEE SATO	Director	Oct 01 '25	Proposed Sale	5.71	66,000	376,860		Oct 01 04:32 PM
SATO VICKI L	Director	Sep 02 '25	Sale	4.99	22,000	109,811	1,254,391	Sep 03 01:50 PM
SATO VICKI L	Director	Aug 01 '25	Sale	4.99	22,000	109,699	1,276,391	Aug 04 12:27 PM
Eisner Mark	EVP and Chief Medical Officer	Jul 15 '25	Sale	5.47	6,796	37,162	108,204	Jul 17 06:46 PM
Eisner Mark	EVP and Chief Medical Officer	Jul 17 '25	Sale	5.47	3,586	19,629	104,618	Jul 17 06:46 PM
MARK EISNER	Officer	Jul 17 '25	Proposed Sale	5.41	3,586	19,400		Jul 17 04:18 PM
Mark Eisner	Officer	Jul 15 '25	Proposed Sale	5.47	6,796	37,162		Jul 15 08:11 PM
SATO VICKI L	Director	Jul 01 '25	Sale	5.10	22,000	112,207	1,298,391	Jul 02 05:03 PM
VICKI LEE SATO	Director	Jul 01 '25	Proposed Sale	5.04	66,000	332,640		Jul 01 04:25 PM
GEORGE SCANGOS	Former Director	Jun 11 '25	Proposed Sale	5.41	19,957	108,037		Jun 11 05:59 PM
GEORGE SCANGOS	Former Director	Jun 10 '25	Proposed Sale	5.48	50,000	273,885		Jun 10 05:04 PM
GEORGE SCANGOS	Former Director	Jun 09 '25	Proposed Sale	5.41	50,000	270,590		Jun 09 05:55 PM
Napolitano Janet	Director	Jun 02 '25	Sale	5.05	3,200	16,149	16,416	Jun 02 07:26 PM
JANET ANN NAPOLITANO	Director	Jun 02 '25	Proposed Sale	4.94	3,200	15,808		Jun 02 04:29 PM
De Backer Marianne	Chief Executive Officer	Apr 03 '25	Sale	5.95	79,712	474,239	769,505	Apr 04 04:23 PM
Marianne De Backer	Officer and Director	Apr 03 '25	Proposed Sale	5.95	79,712	474,239		Apr 03 07:50 PM
de Verneuil Vanina	EVP and General Counsel	Feb 26 '25	Sale	9.14	7,373	67,402	79,460	Feb 27 12:39 PM
VANINA DE VERNEUIL	Officer	Feb 26 '25	Proposed Sale	9.10	7,373	67,094		Feb 26 04:23 PM
SCANGOS GEORGE A	Director	Feb 24 '25	Sale	9.45	10,056	95,063	698,239	Feb 25 03:44 PM
HANLY ANN M.	EVP & Chief Technology Officer	Feb 24 '25	Sale	9.45	14,168	133,936	117,901	Feb 25 03:43 PM
Sabatini Brent	SVP, Chief Accounting Officer	Feb 24 '25	Sale	9.45	1,562	14,766	46,627	Feb 25 03:37 PM
De Backer Marianne	Chief Executive Officer	Feb 24 '25	Sale	9.45	16,122	152,408	849,217	Feb 25 03:36 PM
de Verneuil Vanina	EVP and General Counsel	Feb 24 '25	Sale	9.45	5,140	48,590	86,833	Feb 25 03:34 PM
George Scangos	Director	Feb 24 '25	Proposed Sale	9.45	10,056	95,063		Feb 24 08:57 PM
Brent Sabatini	Officer	Feb 24 '25	Proposed Sale	9.45	1,562	14,766		Feb 24 08:57 PM
Ann Hanly	Officer	Feb 24 '25	Proposed Sale	9.45	14,168	133,936		Feb 24 08:56 PM
Vanina de Verneuil	Officer	Feb 24 '25	Proposed Sale	9.45	5,140	48,590		Feb 24 08:40 PM
Marianne De Backer	Officer and Director	Feb 24 '25	Proposed Sale	9.45	16,122	152,408		Feb 24 08:38 PM
SCANGOS GEORGE A	Director	Feb 18 '25	Sale	9.81	10,964	107,575	708,295	Feb 19 07:11 PM
George Scangos	Director	Feb 18 '25	Proposed Sale	9.81	10,964	107,575		Feb 18 07:50 PM

RARE

Ultragenyx Pharmaceutical Inc

VIR

Vir Biotechnology Inc

Upgrade your FINVIZ experience